Singapore, Singapore

Hengky Chang

This inventor holds 2 USPTO granted patents. Top assignee: Empire Technology Development LLC. Active years: 2015-2018.


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2015-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Hengky Chang in Nanoscale Collagen Technology

Introduction

Hengky Chang is a notable inventor based in Singapore, SG. He has made significant contributions to the field of biomedical engineering, particularly in the development of nanoscale collagen particles. With a total of 2 patents, his work focuses on enhancing cell seeding and wound healing processes.

Latest Patents

Hengky Chang's latest patents include innovations related to nanoscale collagen particles and membranes. These particles are produced through an embrittling and attrition process that reduces the size of collagen particles to the nanoscale. The resulting nanoscale collagen particles exhibit numerous beneficial properties, making them ideal for applications in cell seeding and wound healing. Furthermore, these particles can be incorporated into biocompatible compositions, which are useful for wound treatment and management, as well as in cell cultures and tissue engineering implants.

Career Highlights

Hengky Chang is currently associated with Empire Technology Development LLC, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on medical treatments and tissue engineering.

Collaborations

Hengky Chang collaborates with fellow inventor Henry Leung, contributing to the innovative environment at Empire Technology Development LLC.

Conclusion

Hengky Chang's contributions to the field of nanoscale collagen technology highlight his role as a leading inventor in biomedical engineering. His patents pave the way for advancements in wound healing and tissue engineering applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…